Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Maxwell Biosciences Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, indicating that the company's current applications involve different technical sub-specialties. This distribution requires the practitioner to navigate two separate examination paths within the patent office. The busiest examiner is SCOTLAND, REBECCA LYNN, who is handling 1 busiest examiner pending action.
Because the 2 pending office actions are assigned to 2 distinct examiners, the portfolio's current workload is distributed equally among the assigned personnel. This arrangement means that each application will be subject to the unique examination style of a different individual. Practitioners should be prepared to address the specific technical concerns of 2 distinct art units, as this variety suggests that the applications cover diverse aspects of the Biotechnology & Pharmaceuticals field. Managing the current docket requires a tailored approach for each pending matter to ensure effective communication with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17606761 | HALOGENATED ANTIMICROBIAL PEPTOIDS | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17606761 | HALOGENATED ANTIMICROBIAL PEPTOIDS | REYNOLDS, FRED H | 1658 | §103 | Final Rejection | — | Pending | Oct 27, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMaxwell Biosciences Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Fred H Reynolds has the most, with 1 of Maxwell Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
